Phase i study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 5, 2013, Pages 1089-1096

  Gadgeel, Shirish M ^a   Lew, Danika L ^b   Synold, Timothy W ^c   Lorusso, Patricia ^a   Chung, Vincent ^c   Christensen, Scott D ^d   Smith, David C ^e   Kingsbury, Laura ^f   Hoering, Antje ^b   Kurzrock, Razelle ^g  

^a WAYNE STATE UNIVERSITY   (United States)

^b SWOG STATISTICAL CENTER   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f SWOG Data Operations Center   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Everolimus; Her2; Lapatinib; mTOR; Phase I

Indexed keywords

EVEROLIMUS; LAPATINIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; STEADY STATE; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COHORT ANALYSIS; DOSE RESPONSE; DRUG INTERACTION; EPIDEMIOLOGY; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIROLIMUS; TOR SERINE-THREONINE KINASES; UNITED STATES; YOUNG ADULT;

EID: 84887187698     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2297-4     Document Type: Article

References (27)

1. Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7(7):505-516 (Pubitemid 44036456)
2. Cameron DA, Stein S (2008) Drug insight: intracellular inhibitors of HER2 - clinical development of lapatinib in breast cancer. Nat Clin Pract Oncol 5(9):512-520
3. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733-2743 (Pubitemid 46021510)
4. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8(8):627-644
5. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449-456
6. Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514-523
7. Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520-529
8. La MS, Galetti M, Alfieri RR et al (2009) Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochem Pharmacol 78(5):460-468
9. Miller TW, Forbes JT, Shah C et al (2009) Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res 15(23):7266-7276
10. Buck E, Eyzaguirre A, Brown E et al (2006) Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 5(11):2676-2684 (Pubitemid 44848994)
11. Koch KM, Reddy NJ, Cohen RB et al (2009) Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol 27(8):1191-1196
12. Ratain MJ, Cohen EE (2007) The value meal: how to save 1,700 per month or more on lapatinib. J Clin Oncol 25(23):3397-3398 (Pubitemid 47310874)
13. Streit F, Armstrong VW, Oellerich M (2002) Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. Clin Chem 48(6 Pt 1):955-958 (Pubitemid 34587603)
14. Hsieh S, Tobien T, Koch K, Dunn J (2004) Increasing throughput of parallel on-line extraction liquid chromatography/electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug development. Rapid Commun Mass Spectrom 18(3):285-292 (Pubitemid 38166100)
15. Goudar RK, Shi Q, Hjelmeland MD et al (2005) Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4(1):101-112 (Pubitemid 40268071)
16. Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY (2007) Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 13(9):2795-2803 (Pubitemid 46788049)
17. Schoffski P, Reichardt P, Blay JY et al (2010) A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol 21(10):1990-1998
18. Morrow PK, Wulf GM, Ensor J et al (2011) Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 29(23):3126-3132
19. Milton DT, Riely GJ, Azzoli CG et al (2007) Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 110(3):599-605 (Pubitemid 47106149)
20. Bullock KE, Petros WP, Younis I et al (2011) A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Cancer Chemother Pharmacol 67(2):465-474
21. Riely GJ, Kris MG, Zhao B et al (2007) Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13(17):5150-5155 (Pubitemid 47502083)
22. Christodoulou C, Murray S, Dahabreh J et al (2008) Response of malignant thymoma to erlotinib. Ann Oncol 19(7):1361-1362 (Pubitemid 351911975)
23. Moroney J, Fu S, Moulder S et al (2012) Phase I study of antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin. Clin Cancer Res 18(20):5796-5805
24. Wheeler J, Hong D, Swisher SG et al (2013) Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. Oncotarget 4(6):890-898
25. Yunokawa M, Koizumi F, Kitamura Y et al (2012) Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. Cancer Sci 103(9):1665-1671
26. Janku F, Wheler JJ, Westin SN et al (2012) Pi3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30:777-782
27. Janku F, Wheler JJ, Naing A et al (2013) PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 73:276-284